Ftse Mib
34.160,97
1,25%
DAX
19.984,32
0,74%
S&P 500
5.970,84
-1,11%
NASDAQ
19.722,03
-1,49%
Bitcoin
95.024,72
-0,12%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cullinan Therapeutics Inc (CGEM) Cullinan Therapeutics Inc (CGEM) Notizie

Cullinan Therapeutics Inc

CGEM
12,02
-0,88 (-6,82%)
28 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
20/12/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202423:05EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
14/11/202416:01GLOBECullinan Therapeutics Announces Preclinical Data for..
08/11/202420:17EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
07/11/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202413:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202413:06EDGAR2Form 8-K - Current report
07/11/202413:00GLOBECullinan Therapeutics Provides Corporate Update and Reports..
05/11/202413:00GLOBECullinan Therapeutics to Participate in Fireside Chat at..
04/11/202413:00GLOBECullinan Therapeutics to Present Preclinical Data for..
16/10/202413:17EDGAR2Form 8-K - Current report
16/10/202413:00GLOBECullinan Therapeutics Receives U.S. FDA Clearance of..
17/9/202413:13EDGAR2Form 8-K - Current report
17/9/202413:00GLOBECullinan Therapeutics Receives Approval to Initiate its..
16/9/202413:00GLOBECullinan Therapeutics Announces Submission of..
14/9/202410:15GLOBECullinan Therapeutics Presents Positive Updated Data from..
09/9/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202422:27EDGAR2Form 144 - Report of proposed sale of securities
28/8/202414:00GLOBECullinan Therapeutics to Participate in Upcoming Investor..
08/8/202413:00GLOBECullinan Therapeutics Provides Corporate Update and Reports..
05/6/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
04/6/202423:06EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
03/6/202414:12EDGAR2Form 8-K - Current report
01/6/202413:00GLOBECullinan Therapeutics Announces Positive Initial Data from..
24/5/202414:00GLOBECullinan Therapeutics to Participate in Fireside Chat at TD..
23/5/202423:07EDGAR2Form 8-K - Current report
23/5/202423:04GLOBECullinan Therapeutics to Present First Data for CLN-619, a..
16/5/202422:10EDGAR2Form S-3 - Registration statement under Securities Act of..
16/5/202412:42EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16/5/202412:40EDGAR2Form DEF 14A - Other definitive proxy statements
15/5/202422:05GLOBECullinan Therapeutics Provides Corporate Update and Reports..
09/5/202401:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/5/202422:32EDGAR2Form 144 - Report of proposed sale of securities
29/4/202413:00GLOBECullinan Therapeutics Announces Appointment of Mary Kay..
24/4/202416:09GLOBECullinan Therapeutics to Present Clinical Data from Phase 1..
16/4/202413:00GLOBECullinan Therapeutics Announces Strategic Expansion into..
16/4/202412:59GLOBECullinan Therapeutics Announces Oversubscribed $280 million..
14/3/202412:00GLOBECullinan Oncology Provides Corporate Update and Reports..
01/3/202413:00GLOBECullinan Oncology Announces U.S. FDA Clearance of..
27/2/202414:00GLOBECullinan Oncology to Participate in Upcoming Investor..
23/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202403:01EDGAR2Form SC 13G - Statement of acquisition of beneficial..
03/2/202403:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:43EDGAR2Form 144 - Report of proposed sale of securities
31/1/202401:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 12,88 Min: 11,81 Max: 12,88
Chiusura: 12,90

La tua Cronologia

NASDAQ
CGEM
Cullinan Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network